Literature DB >> 15511356

[Cross-cultural adaptation of a questionnaire for measuring the quality of life of patients taking oral anticoagulants].

R Sánchez González1, M Yanes Baonza, A Cabrera Majada, J M Ferrer García-Borrás, R Alvarez Nido, E Barrera Linares.   

Abstract

OBJECTIVE: To adapt to Spanish culture and language a questionnaire developed to evaluate the quality of life of patients taking oral anticoagulation treatment (OAT) and to measure its validity.
DESIGN: A descriptive observation study to validate an instrument to measure health-related quality of life.
SETTING: Primary and specialist care. PARTICIPANTS: 225 patients, all the patients at our centre who were on OAT and a consecutive sample of patients on OAT from the referral hospital's haemotology service. MAIN MEASUREMENTS: Direct translation, back-translation, and pilot study. Factor analysis and item-dimension grouping, internal consistency analysis and analysis of the item-total correlation of the definitive version of the questionnaire in Spanish.
RESULTS: Mean age was 65 (SD=13 years); 51% were women; 45.8% were monitored in PC. Validity study: factor analysis extracted 5 factors that explained 41.62% of total variance value and obtained a grouping different from the original; Cronbach's alpha was .82 overall and ran from .56 to .74 in the various dimensions; and item-total correlation analysis had statistically significant values, except for question 29.
CONCLUSIONS: After adaptation to Spanish culture and language of a questionnaire developed to evaluate the quality of life of patients taking OAT, it was found to be a useful instrument, valid for use in our milieu.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15511356     DOI: 10.1016/s0212-6567(04)79515-3

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  6 in total

1.  [Quality of life of patients treated with oral anticoagulants].

Authors:  M Yanes Baonza; A Cabrera Majada; J M Ferrer García-Borrás; R Sánchez González
Journal:  Aten Primaria       Date:  2005-09-15       Impact factor: 1.137

2.  Development and validation of a new questionnaire measuring treatment satisfaction in patients with non-valvular atrial fibrillation: SAFUCA®.

Authors:  Miguel A Ruiz; José Ramón González-Porras; José Luis Aranguren; Eduardo Franco; Fernando Villasante; José Tuñón; Tomás José González-López; Marina de Salas-Cansado; Javier Soto
Journal:  Qual Life Res       Date:  2016-12-18       Impact factor: 4.147

3.  Quality of life with rivaroxaban in patients with non-valvular atrial fibrilation by therapeutic compliance.

Authors:  Emilio Márquez-Contreras; Nieves Martell-Claros; Vicente Gil-Guillén; Mariano De la Figuera-Von Wichmann; Eugenio Sánchez-López; Ines Gil-Gil; Sara Márquez-Rivero
Journal:  Qual Life Res       Date:  2017-01-06       Impact factor: 4.147

4.  New oral anticoagulants vs vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation.

Authors:  Josep M Alegret; Xavier Viñolas; Miguel A Arias; Antoni Martínez-Rubio; Pablo Rebollo; Carles Ràfols; José L Martínez-Sande
Journal:  Int J Med Sci       Date:  2014-05-01       Impact factor: 3.738

5.  Health-related quality of life in nonvalvular atrial fibrillation patients with controlled or uncontrolled anticoagulation status.

Authors:  José Felipe Varona; José Miguel Seguí-Ripoll; Cristina Lozano-Duran; Luis Miguel Cuadrado-Gómez; Juan Bautista Montagud-Moncho; Antonio Ramos-Guerrero; José Carlos Mirete-Ferrer; Esther Donado; Javier García-Alegría
Journal:  Health Qual Life Outcomes       Date:  2020-12-11       Impact factor: 3.186

6.  Sense of Coherence and Quality of Life in Patients Treated with Antivitamin K Oral Anticoagulants: A Cross-Sectional Study.

Authors:  Ana Anguas-Gracia; Ana Belén Subirón-Valera; Beatriz Rodríguez-Roca; Ángel Gasch-Gallén; Isabel Antón-Solanas; Fernando Urcola-Pardo
Journal:  Int J Environ Res Public Health       Date:  2021-02-09       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.